Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
21.43
+0.34 (1.61%)
Aug 13, 2025, 4:00 PM - Market closed
Pharvaris Employees
Pharvaris had 108 employees as of December 31, 2024. The number of employees increased by 26 or 31.71% compared to the previous year.
Employees
108
Change (1Y)
26
Growth (1Y)
31.71%
Revenue / Employee
n/a
Profits / Employee
-$1,526,633
Market Cap
1.55B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PHVS News
- 1 day ago - Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 21 days ago - Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations - Seeking Alpha
- 22 days ago - Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 22 days ago - Pharvaris Announces Proposed Public Offering of Ordinary Shares - GlobeNewsWire
- 27 days ago - Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success - Seeking Alpha
- 5 weeks ago - Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 - GlobeNewsWire
- 6 weeks ago - Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit - GlobeNewsWire
- 2 months ago - Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress - GlobeNewsWire